SK Chemicals applies for sales approval of dementia treatment from US FDA

Published: 2016-04-05 10:12:23

Updated: 2016-04-06 14:09:34

A SK Chemicals’ patch-type dementia treatment will knock on the door of the U.S. market.

SK Chemicals(CEO Man-hoon Park) announced it completed application of the sales approval of ‘SID710,’ a patch-type dementia treatment, from the U.S. Food and Drug Administration on April 1(March 31 U.S. time) at a local time.

SID710 has acquired approval as the first Excelon patch generic in the EU in 201...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.